Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06032195
Other study ID # CL-N-HTX-Paed-II/10/20
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date August 15, 2023
Est. completion date December 2025

Study information

Verified date April 2023
Source Dr. F. Köhler Chemie GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this prospective randomized single blind multicenter phase II study is to compare organ perfusion with Custodiol-N and Custodiol in heart transplantation in children of all ages (birth to <18 years) being listed on the waiting list for heart transplantation. The main question it aims to answer is: to compare the safety of Custodiol-N in heart transplantation in children in comparison to its precursor product Custodiol. Participants will receive either a heart to be transplanted, either perfused with Custodiol-N or Custodiol to Researchers will compare the two solutions to see if the new solution Custodiol-N is safe in heart transplantation in children.


Description:

Orthotopic Heart transplantation (or cardiac transplantation) is a procedure performed in patients with end stage heart failure when other treatments have failed. The surgical procedures for orthotopic heart transplantation are essentially the same in adult and paediatric patients . Due to anatomical variants in congenital heart disease the procurement procedure may be modified with regard to the extent of the Vena cava superior and the great vessels. In implantation most frequently the bicaval technique is used but the biatrial technique which is leaving the back wall of both atria in situ may also be employed. A main difference between adult and paediatric heart transplantation (HTx) are the indications for transplantation: In adults the majority of patients undergo HTx as treatment of end stage heart failure due to cardiomyopathy or severe coronary artery disease when other treatments have failed. Infants younger than one year of age congenital heart disease (CHD) is the most common diagnosis representing more than every second case followed by dilated cardiomyopathy (DCM) in more than one third of cases. In older patients DCM is the most frequent underlying diagnosis. CHD may include patients who have undergone corrective surgery and in whom myocardial dysfunction develops later .


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 15
Est. completion date December 2025
Est. primary completion date April 2025
Accepts healthy volunteers No
Gender All
Age group 24 Hours to 17 Years
Eligibility Inclusion Criteria: - Age from birth to less than18 years - Recipients awaiting their first transplant - Ability of the patients and/ or their legal guardians to understand character and individual consequences of the clinical trial - written informed consent of the patients and/ or their legal guardians (must be available before enrolment in the study) - Patient listed on the waiting list for heart transplantation Exclusion Criteria: - Patients who have participated within 30 days or are still participating in any other interventional studies - history of severe organic disease other than concerning the heart - history/demonstration of HIV antibodies or AIDS - multiorgan transplantation - machine-perfused organ - the explantation team is affiliated to another clinic than transplantation team - Failing Fontan patients - Patients who have been incarcerated or involuntarily institutionalized by court order or by the authorities - Pregnancy and lactation

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Custodiol-N
heart will preserved in and will be treated with Custodiol-N solution
Custodiol
heart will preserved in and will be treated with Custodiol solution

Locations

Country Name City State
Germany Deutsches Herzzentrum der Charité Berlin
Germany Universitätsklinikum Gießen (UKGM), Kinderherzzentrum, Klinikum für Kinderherzchirurgie Gießen
Germany Klinikum der Universität München (LMU), Klinik und Poliklinik für Herzchirurgie, Chirurgische Klinik München

Sponsors (1)

Lead Sponsor Collaborator
Dr. F. Köhler Chemie GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary adverse event reporting Safety assessment up to 3 months
Secondary heart rate vital parameters up to day 7 after release of the aortic cross clamp
Secondary blood pressure (systolic (SBP) and diastolic (DBP)) vital parameters up to day 7 after release of the aortic cross clamp
Secondary body temperature vital parameters up to day 7 after release of the aortic cross clamp
Secondary concentration of cardiac troponin laboratory tests up to day 7 after release of the aortic cross clamp
Secondary concentration of creatinine kinase (CK-MB) laboratory tests up to day 7 after release of the aortic cross clamp
Secondary (SBP (systolic blood pressure), DBP (diastolic blood pressure)) Haemodynamics from termination of cardiopulmonary bypass until transfer to intensive care unit
Secondary Heart Rhythm (HR) Haemodynamics from termination of cardiopulmonary bypass until transfer to intensive care unit
Secondary Pulmonary artery pressure (PAP (if available)) Haemodynamics from termination of cardiopulmonary bypass until transfer to intensive care unit
Secondary Cerebrovascular resistance (CVR (if available)) Haemodynamics from termination of cardiopulmonary bypass until transfer to intensive care unit
Secondary Death survival up to 12 months
Secondary function of transplanted organ (heart) Graft survival up to 3 months
Secondary Readmission to intensive care unit (ICU) return to intensive care unit up to 3 months
Secondary Length of ICU stays duration of stay in intensive care unit up to 3 months
Secondary Catecholamine requirement (yes/no) up to day 7
Secondary Antihypertensives intake (yes/no) up to 12 months
Secondary Milrinone support (yes/no) up to day 7
Secondary Need for pacemaker therapy (yes/no) up to day 7
Secondary Left and right ventricular assist device (LVAD, RVAD) Device therapy (each yes/no) up to 3 months
Secondary Extracorporeal membrane oxygenation (ECMO) Device therapy (each yes/no) up to 3 months
Secondary Biventricular assist Device (BIVAD) or percutaneous LVAD Device therapy (each yes/no) up to 3 months
Secondary Ejection fraction Echocardiographic markers of function and rejection up to day 7
Secondary enddiastolic and endsystolic ventricle Echocardiographic markers of function and rejection up to day 7
Secondary Cardiac arrhythmias occurrence, severity, type up to day 7
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06035991 - First Clinical Evaluation of Heart Transplantation With Grafts Preserved Using an Ex-vivo Extended Perfusion System N/A
Recruiting NCT01927614 - Advanced Cardiac Imaging in Cardiac Allograft Vasculopathy N/A
Recruiting NCT01705015 - Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement N/A
Completed NCT01655563 - Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation Phase 2
Completed NCT01028599 - Effect of Physical Training on Oxygen Uptake and Endothelial Function in Heart Transplant Recipients N/A
Completed NCT00531921 - Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival N/A
Terminated NCT00420537 - Shift to Everolimus (RAD) Kidney Sparing Study Phase 4
Enrolling by invitation NCT03292861 - The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients Phase 2
Recruiting NCT04924491 - Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Prevent Rejection in Heart Transplant Children Phase 1/Phase 2
Recruiting NCT05270902 - Haemoadsorption During Heart Transplantation N/A
Completed NCT05289180 - Brachial Right Ventricle - Endomyocardial Biopsy
Recruiting NCT03687723 - Observational Study of the Clinical Use of the OCS™ Heart
Completed NCT01091194 - Effect of Exercise After Heart Transplantation Phase 2
Withdrawn NCT00780637 - Brachial Artery t-PA Release in Heart Transplant Recipients N/A
Withdrawn NCT00780377 - Intracoronary Bradykinin Mediated t-PA Release in Heart Transplant Recipients N/A
Terminated NCT00678002 - Quality of Life in Pediatric Transplant Patients
Completed NCT01182571 - Exploration of Fatigue, Uncertainty, Depression and Quality of Life in Heart Transplantation Recipients N/A
Terminated NCT00121784 - Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients Phase 4
Withdrawn NCT00572286 - Non-invasive Evaluation of Heart Transplant Rejection- Pilot Study N/A
Completed NCT00123331 - Rapamycin Use in Calcineurin Inhibitor (CNI)-Free Immunosuppression for Stabilization/Improvement of Renal Function After Heart Transplantation Phase 4